Guidelines

• ASAS & EULAR

  • #01 :: Axial spondyloarthritis ASAS&EULAR recommendations 2016 update
  • #02 :: Management of early arthritis EULAR recommendations 2016 update
  • #03 :: Rheumatoid arthritis EULAR recommendations 2016 update
  • #04 :: Treating juvenile idiopathic arthritis to target: recommendations of an international task force
  • #05 :: EULAR evidence-based recommendations for the management of gout 2016 update
  • #06 :: Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
  • #07 :: Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
  • #08 :: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
  • #09 :: The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
  • #10 :: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies 2015 update
  • #11 :: Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis
• 
  • #12 :: Axial spondyloarthritis Portuguese recommendations 2016
  • #13 :: Rheumatoid arthritis Portuguese recommendations 2016 update
  • #14 :: Use of biological therapies in children and adolescents with Juvenile Idiopathic Arthritis Portuguese recommendations 2016 update
  • #15 :: Portuguese recommendations for the diagnosis and management of Gout
  • #16 :: Portuguese recommendations for the use of methotrexate in rheumatic diseases – 2016 update
  • #17 :: Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy
  • #18 :: Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy
  • #19 :: Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis 2015 update

• OUTROS

  • #20 :: Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting
  • #21 :: The British Society for Rheumatology Guideline for the Management of Gout
  • #22 :: Screening of Inflammatory Bowel Disease and Spondyloarthritis for Referring Patients Between Rheumatology and Gastroenterology
  • #23 :: Management of patients with inflammatory bowel disease and spondyloarthritis
  • #24 :: Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
  • #25 :: Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
  • #26 :: Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study
  • #27 :: Wound Healing Complications and Infection Following Surgery for Rheumatoid Arthritis
  • #28 :: Treatment of psoriatic arthritis: management recommendations
  • #29 :: Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery
  • #30 :: A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control
  • #31 :: The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis
  • #32 :: Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers